Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 28;19(1):400.
doi: 10.1186/s13023-024-03381-w.

Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis

Chang Liu  1 , Yao Wu  1 , Fangxu Wang  1 , Shuang Sun  1 , Jiayin Wei  1 , Libo Tao  2
Affiliations

Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis

Chang Liu et al. Orphanet J Rare Dis. .

Abstract

Background: Edaravone has been widely used in amyotrophic lateral sclerosis (ALS) treatment, and a sublingual (SL) tablet has been developed to offer a more convenient alternative for injection. We present a cost-utility analysis to comprehensively evaluate the costs and health outcomes of oral and intravenous edaravone for the treatment of ALS in Chinese medical context.

Methods: Cost-utility analysis of SL tablets of edaravone versus intravenous edaravone at home was performed by constructing a 20-year Markov model of ALS stage 1-4 and death. The data were extracted from the literature with model assumptions. Typical sensitivity analysis and scenario analysis for administering SL tablets at home versus intravenous tablets at the hospital were performed.

Results: In the base case analysis, with SL tablets and intravenous injections both at home, the model estimated an additional cost of ¥12,670.04 and an additional 0.034 QALYs over 20 years (life time) of modeling analysis, and the ICER was ¥372,648.24 per QALY. However, in the scenario of intravenous administration at the hospital, SL tablet was demonstrated dominance to intravenous injection.

Conclusions: Using 3 times the GDP per capita of China in 2023 as the threshold, the SL tablet edaravone was not cost-effective in the context of home treatment for both formulationst, but was dominance to intravenous injection in hospital treatment. The results highlighted the importance of treatment context for health economic analysis.

Keywords: Amyotrophic lateral sclerosis; Cost-utility analysis; Edaravone; Sublingual tablet.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
ALS Markov Model. ALS Amyotrophic lateral sclerosis
Fig. 2
Fig. 2
Cost-utility tornado chart. ICER Incremental cost effectiveness ratio, QALY Quality adjusted life year, SL Sublingual, IV Intravenous, TP Transition probability, ALS Amyotrophic lateral sclerosis
Fig. 3
Fig. 3
Cost-utility plane of SL versus IV edaravone. QALYs Quality adjusted life years, SL Sublingual, IV Intravenous, PSA Probabilistic sensitivity analysis
Fig. 4
Fig. 4
Cost-utility acceptability curve of SL versus IV edaravone. SL Sublingual, IV Intravenous
See this image and copyright information in PMC

References

    1. Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;20(3):17085. 10.1038/nrdp.2017.85. - PubMed
    1. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344(22):1688–700. 10.1056/NEJM200105313442207. - PubMed
    1. Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009;10(5–6):310–23. 10.3109/17482960802566824. - PMC - PubMed
    1. Xu L, Chen L, Wang S, Feng J, Liu L, Liu G, et al. Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study. J Neurol Neurosurg Psychiatry. 2020;91(5):520–5. 10.1136/jnnp-2019-322317. - PubMed
    1. Jun KY, Park J, Oh KW, Kim EM, Bae JS, Kim I, et al. Epidemiology of ALS in Korea using nationwide big data. J Neurol Neurosurg Psychiatry. 2019;90(4):395–403. 10.1136/jnnp-2018-318974. - PMC - PubMed

MeSH terms